Clinical Trial Update: AVTX-801 D-galactose Supplementation in SLC35A2-CDG [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (AVTX-801) using D-galactose supplementation for SLC35A2-CDG is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Slc35a2-cdg

Drugs mentioned

• AVTX-801 (D-galactose)

Snippet

Sponsor: Eva Morava-Kozicz | Conditions: SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation | Phase 2 | Status: NOT_YET_RECRUITING